B-cell receptor specific for diphtheria toxoid (BCR-DT)

B-cell receptors (BCRs) specific for diphtheria toxoid epitopes are membrane-bound immunoglobulins expressed on the surface of B lymphocytes that recognize the inactivated form of the toxin produced by Corynebacterium diphtheriae (Janeway's Immunobiology, 2016). These receptors are the primary targets of diphtheria-containing vaccines, such as DTaP and Tdap, which aim to elicit a robust and lasting adaptive immune response. Upon binding to the toxoid, the BCR initiates a signaling cascade that leads to B-cell proliferation, affinity maturation, and the generation of long-lived memory B cells and plasma cells (CDC, 2022). The resulting antibodies neutralize the active diphtheria toxin by blocking its ability to bind to host cell receptors, thereby preventing the inhibition of protein synthesis and subsequent tissue necrosis (StatPearls, 2023). In clinical practice, the success of targeting these receptors is measured by serum antitoxin levels, where a titer of 0.1 IU/mL is generally considered protective (WHO, 2023). Understanding the specificity and activation of these BCRs is crucial for maintaining population immunity and developing improved vaccine formulations against diphtheria (Plotkin's Vaccines, 2018).

Other names

Anti-diphtheria toxoid B-cell receptorDiphtheria toxoid-specific BCRDT-binding B-cell receptorDiphtheria toxoid-specific immunoglobulin

The diphtheria toxoid acts as an antigen that binds to the variable regions of the specific B-cell receptor, inducing receptor clustering and signaling via the CD79A/B complex (Janeway's Immunobiology, 2016). This interaction facilitates antigen internalization, processing, and presentation to T-helper cells, ultimately leading to the differentiation of B cells into plasma cells that secrete high-affinity neutralizing IgG antibodies (PubMed: 28250444).